[HPV - A different view on Head and Neck Cancer]

Area of Science:

• Oncology
• Virology
• Genetics

Background:

• Head and neck cancer is a significant global health issue, with over 500,000 new cases annually.
• Oropharyngeal squamous cell carcinomas (OSCC) are increasingly linked to human papillomavirus (HPV), distinguishing them from traditional risk factor-driven cancers.
• HPV-associated and HPV-negative OSCC represent distinct biological entities with differing treatment responses and prognoses.

Purpose of the Study:

• To explore the distinct biological characteristics and therapeutic implications of HPV-associated OSCC.
• To discuss the potential for targeted therapies, including immunotherapy and de-intensified treatment strategies, for HPV OSCC.
• To highlight the role of emerging biomarkers and preventative measures for HPV OSCC.

Main Methods:

• Review of current literature on HPV-associated OSCC pathogenesis, treatment response, and prognosis.
• Analysis of the role of viral oncoproteins, genetic, and epigenetic alterations in HPV OSCC development.
• Investigation of targeted therapy concepts like immunotherapy (e.g., checkpoint inhibitors) and the utility of liquid biopsies.

Main Results:

• HPV-associated OSCC exhibits unique biological features driven by viral oncoproteins and host genetic/epigenetic changes.
• Patients with HPV OSCC generally show improved treatment responses, supporting therapy de-intensification and targeted approaches.
• Immunotherapy, particularly checkpoint inhibitors, is a promising avenue for HPV OSCC treatment.
• Liquid biopsies offer potential for monitoring disease and detecting treatment failure through biomarkers like viral DNA and tumor mutations.

Conclusions:

• HPV-associated OSCC is a distinct clinical and biological entity requiring tailored management strategies.
• Targeted therapies, especially immunotherapy, and advanced monitoring via liquid biopsies hold significant potential for improving outcomes in HPV OSCC.
• Primary prevention through HPV vaccination in both genders is crucial for reducing the incidence of HPV OSCC.